Beacon Therapeutics Appoints Dr. Daniel Chung as Chief Medical Officer
Company - People | Jun 09, 2025 | oxford sciences innovation
Beacon Therapeutics Holdings Limited, a prominent clinical-stage biotechnology company specializing in therapies for blinding retinal diseases, has announced the appointment of Dr. Daniel Chung as the new Chief Medical Officer. Dr. Chung brings over 30 years of expertise in clinical ophthalmology, academic research, and gene therapy development. Prior to this role, he was the Chief Medical Officer at SparingVision and has held significant positions at Spark Therapeutics, where he was instrumental in developing Luxturna, the first FDA and EMA-approved gene therapy for a genetic eye disease. His appointment coincides with a pivotal time for Beacon Therapeutics as they near the completion of enrollment in their Phase 2/3 VISTA trial for X-linked retinitis pigmentosa (XLRP). Dr. Chung's extensive experience across various retinal gene therapy initiatives and his academic background makes him a valuable addition to the company as they advance their pipeline towards regulatory approval and potential treatments for rare retinal diseases.
Sectors
- Biotechnology
- Healthcare
- Pharmaceuticals
Geography
- United Kingdom – Beacon Therapeutics is based in the UK, detailing their operations and strategic directions from there.
- United States – Dr. Daniel Chung’s past experience and academic background prominently feature institutions in the USA, adding to the article's geographical relevance.
Industry
- Biotechnology – The article centers around Beacon Therapeutics, a biotechnology company focusing on developing gene therapies for retinal diseases.
- Healthcare – The activities and advancements discussed in the article relate to medical treatments and developments in the healthcare sector, specifically gene therapy for eye diseases.
- Pharmaceuticals – Gene therapy, a significant aspect of pharmaceuticals, is a primary focus in the article with the development of treatments for genetic eye conditions.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Dr. Daniel Chung | Chief Medical Officer | People | Newly appointed as Chief Medical Officer at Beacon Therapeutics, bringing extensive experience in ophthalmology and gene therapy. |
| Beacon Therapeutics Holdings Limited | Target Company | Company | A clinical-stage biotechnology company developing gene therapies for retinal diseases. |
| Oxford Sciences Innovation | PE Firm | Company | A private equity firm involved with investments in Beacon Therapeutics. |
| SparingVision | Former Employer | Company | Dr. Daniel Chung's previous employer, a clinical-stage genomic medicine company. |
| Spark Therapeutics | Former Employer | Company | A company where Dr. Chung contributed to the development of a groundbreaking gene therapy. |
| Lance Baldo, M.D. | Chief Executive Officer | People | CEO of Beacon Therapeutics who is quoted welcoming Dr. Chung. |